

LA JOLLA PHARMACEUTICAL CO

Form 8-K

June 10, 2004

Table of Contents

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549**

FORM 8-K

**CURRENT REPORT
PURSUANT TO SECTION 13 or 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934**

Date of report (Date of earliest event reported): June 9, 2004

La Jolla Pharmaceutical Company

(Exact Name of Registrant as Specified in Charter)

Delaware

0-24274

33-0361285

(State or Other Jurisdiction
of Incorporation)

(Commission
File Number)

(IRS Employer
Identification No.)

6455 Nancy Ridge Drive, San Diego, California

92121

(Address of Principal Executive Offices)

(Zip Code)

Registrant's telephone number, including area code: (858) 452-6600

N/A

(Former Name or Former Address, if Changed Since Last Report)

TABLE OF CONTENTS

Item 5. Other Events and Required FD Disclosure.

Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.

SIGNATURES

EXHIBIT INDEX

EX-99.1

EX-99.2

Table of Contents

Item 5. Other Events and Required FD Disclosure.

On June 9, 2004, the Company issued a press release announcing that Steven B. Engle, the Company's Chief Executive Officer, would present at the Third Annual Needham Biotechnology Conference on June 17, 2004. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

On June 10, 2004, the Company issued a press release announcing that the Company would present previously released results from its Phase 2/3 and Phase 3 clinical trials of Riquent® (abetimus sodium) at EULAR's Annual European Congress of Rheumatology on June 9-12, 2004. A copy of the press release is attached hereto as Exhibit 99.2 and is incorporated herein by reference.

Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.

(c) *Exhibits.* The following exhibits are filed with this report on Form 8-K:

Exhibit Number	Description of Exhibit
99.1	Needham Biotechnology Conference Press Release
99.2	EULAR Annual European Congress of Rheumatology Press Release

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**LA JOLLA PHARMACEUTICAL
COMPANY**

Date: June 10, 2004

By: /s/ Gail A. Sloan
Gail A. Sloan
Vice President of Finance and
Controller

Table of Contents

EXHIBIT INDEX

Exhibit Number	Description of Exhibit
99.1	Needham Biotechnology Conference Press Release
99.2	EULAR Annual European Congress of Rheumatology Press Release